Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
-1.96% $4.50
America/New_York / 17 apr 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 201.05 mill |
EPS: | -0.930 |
P/E: | -4.84 |
Earnings Date: | May 02, 2024 |
SharesOutstanding: | 44.68 mill |
Avg Daily Volume: | 1.806 mill |
RATING 2024-04-17 |
---|
B- |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Neutral | |
Return On Equity: | Strong Sell | |
Return On Asset: | Sell | |
DE: | Neutral | |
P/E: | Neutral | |
Price To Book: | Neutral |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -4.84 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.82x |
Company: PE -4.84 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
$0.119 (-97.35%) $-4.38 |
Date: 2024-04-17 |
Expected Trading Range (DAY) |
---|
$ 3.90 - 5.13 ( +/- 13.64%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-07 | Levine James E. | Buy | 205 008 | Stock Options |
2024-03-07 | Kabbinavar Fairooz | Buy | 205 008 | Stock Options |
2024-03-07 | Smeal Tod | Buy | 205 008 | Stock Options |
2024-03-07 | Erlander Mark | Buy | 510 000 | Stock Options |
2023-12-19 | Pace Gary W | Buy | 30 000 | Common Stock |
INSIDER POWER |
---|
81.73 |
Last 96 transactions |
Buy: 6 518 913 | Sell: 700 088 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $4.50 (-1.96% ) |
Volume | 0.845 mill |
Avg. Vol. | 1.806 mill |
% of Avg. Vol | 46.80 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; metastatic colorectal cancer that is in clinical trials; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company's TROV-053 is also in Phase II clinical trial in combination with Zytiga for metastatic castration-resistant prostate cancer. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.